{"id":17441,"date":"2022-05-23T20:10:57","date_gmt":"2022-05-23T14:40:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17441"},"modified":"2024-09-18T13:25:32","modified_gmt":"2024-09-18T07:55:32","slug":"developmental-and-epileptic-encephalopathy-pipeline-therapies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies","title":{"rendered":"Evaluation of the Advancing Developmental and Epileptic Encephalopathy Treatment Pipeline"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f226a3336f1\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f226a3336f1\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\/#Developmental_and_Epileptic_Encephalopathy_Epidemiology_and_Statistics\" >Developmental and Epileptic Encephalopathy Epidemiology and Statistics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\/#Developmental_and_Epileptic_Encephalopathy_Market_Insights\" >Developmental and Epileptic Encephalopathy Market Insights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\/#Current_Developmental_and_Epileptic_Encephalopathy_Treatment_Landscape\" >Current Developmental and Epileptic Encephalopathy Treatment Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\/#Emerging_Drugs_in_Developmental_and_Epileptic_Encephalopathy_Pipeline\" >Emerging Drugs in Developmental and Epileptic Encephalopathy Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\/#Unmet_Needs_in_Developmental_and_Epileptic_Encephalopathy_Treatment_Domain\" >Unmet Needs in Developmental and Epileptic Encephalopathy Treatment Domain<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\/#Way_Ahead\" >Way Ahead<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often <a href=\"https:\/\/www.delveinsight.com\/blog\/drug-resistant-epilepsy-market-dynamics\">drug-resistant<\/a>, as well as <a href=\"https:\/\/www.delveinsight.com\/report-store\/encephalopathy-pipeline-insight\">encephalopathy<\/a>, which is a term used to describe significant developmental delay or even loss of developmental skills. In Developmental and Epileptic Encephalopathy, cognitive functions are influenced severely by seizures and interictal epileptiform activity, also by the neurobiological process behind Epilepsy. DEEs are also related to gene variants and the onset is usually during early childhood. The effect of seizures on cognitive function is partially dependent on the period of brain maturation in which the seizures occur, which in turn, is dependent on other factors, such as underlying pathology, genetic susceptibility factors, and seizure triggers (e.g., febrile illness). While cognitive impairments are often a consequence of the underlying pathology, independent of seizures, it is also important to recognize that seizures themselves also play a role in developing cognitive impairments.<\/p>\n\n\n\n<p>The syndromes of neonatal-onset epileptic encephalopathy, infantile epileptic encephalopathy, and early childhood include early myoclonic encephalopathy, Ohtahara syndrome, <a href=\"https:\/\/www.delveinsight.com\/blog\/west-syndrome-market\">West syndrome<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\">Dravet syndrome<\/a> (severe myoclonic epilepsy in infancy), <a href=\"https:\/\/www.delveinsight.com\/report-store\/lennox-gastaut-syndrome-market\">Lennox\u2013Gastaut syndrome<\/a> (LGS), Landau\u2013Kleffner syndrome (LKS), Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS), <a href=\"https:\/\/www.delveinsight.com\/report-store\/doose-syndrome-market\">Doose Syndrome<\/a> (myoclonic atonic epilepsy), <a href=\"https:\/\/www.delveinsight.com\/report-store\/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market\">CDKL5 deficiency disorder<\/a> (CDD), <a href=\"https:\/\/www.delveinsight.com\/report-store\/tuberous-sclerosis-complex-market\">Tuberous sclerosis complex <\/a>(TSC), <a href=\"https:\/\/www.delveinsight.com\/report-store\/scn2a-developmental-and-epileptic-encephalopathy-scn2a-pipeline-insight\">SCN8A-Developmental and Epileptic Encephalopathy<\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/kcnq2-developmental-and-epileptic-encephalopathy-kcnq2-dee-market\">KCNQ2-Developmental and Epileptic Encephalopathy.<\/a><\/p>\n\n\n\n<p>The approach to Epileptic Encephalopathy treatment includes some of the general principles and approaches to pediatric epilepsy treatment. The most appropriate anti-epileptic treatment is selected based on the type of epilepsy syndrome. Antiseizure medications includes clobazam, vigabatrin, zonisamide, phenobarbital, benzodiazapines, vigabatrin, and others are used for Developmental and Epileptic Encephalopathy treatment. Steroids therapies, <a href=\"https:\/\/www.delveinsight.com\/blog\/vagus-nerve-stimulator-market\">vagus nerve stimulation<\/a>, ketogenic diet and epilepsy surgery are also used for Developmental and Epileptic Encephalopathy management.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-developmental-and-epileptic-encephalopathy-epidemiology-and-statistics\"><span class=\"ez-toc-section\" id=\"Developmental_and_Epileptic_Encephalopathy_Epidemiology_and_Statistics\"><\/span><strong>Developmental and Epileptic Encephalopathy Epidemiology and Statistics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to various studies by DelveInsight, it is observed that <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-epidemiology-forecast\">Developmental and Epileptic Encephalopathy prevalence<\/a> is higher in men as compared to women. As per an analysis, the total diagnosed prevalent population of Developmental and Epileptic Encephalopathy in the<strong> 7MM<\/strong> was observed to be <strong>235,157<\/strong> in <strong>2021<\/strong>. Epidemiology assessment for DEE indicated that the <strong>United States<\/strong>, in 2021, accounted for approximately<strong> 129,437 <\/strong>diagnosed prevalent cases of DEE, which was the highest among the 7MM.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-0ef0acc1-56d3-494c-a915-5608ef2f906e\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-swl5ssl-553-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-swl5ssl-559-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-swl5ssl-560-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 159.5 71 L 159.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 244.5 71 L 244.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 328.5 71 L 328.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 413.5 71 L 413.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 71 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74.5 71 L 74.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 314.5 L 499 314.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 266.5 L 499 266.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 217.5 L 499 217.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 168.5 L 499 168.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 120.5 L 499 120.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 70.5 L 499 70.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.488866806030273 217)\" x=\"26.488866806030273\" y=\"217\">Diagnosed Prevalent Cases in Thousands<\/text><path class=\"highcharts-axis-line\" d=\"M 75 71 L 75 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-swl5ssl-559-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><rect aria-label=\"7MM, 253. Geography.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"246\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"21.5\" y=\"46.5\"><\/rect><rect aria-label=\"US, 129. Geography.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"126\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"106.5\" y=\"166.5\"><\/rect><rect aria-label=\"Germany, 21. Geography.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"20\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"191.5\" y=\"272.5\"><\/rect><rect aria-label=\"France, 17. Geography.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"17\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"275.5\" y=\"275.5\"><\/rect><rect aria-label=\"Japan, 23. Geography.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"22\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"360.5\" y=\"270.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Diagnosed Prevalent Cases of DEE (in 2021)<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"52\">Developmental and Epileptic Encephalopathy Epidemiology Forecast &#8211; 2032<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(26,23)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">253<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>253<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(111,143)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">129<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>129<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(200,249)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">21<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>21<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(284,252)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">17<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>17<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(369,247)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">23<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>23<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"117.4\" y=\"382\">7MM<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"202.2\" y=\"382\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"287\" y=\"382\">Germany<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"371.8\" y=\"382\">France<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"456.6\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"318\">50<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"270\">100<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"221\">150<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"172\">200<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"124\">250<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"75\">300<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Development and Epileptic Encephalopathy Epidemiology Forecast - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Development and Epileptic Encephalopathy Epidemiology Forecast &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-swl5ssl-560-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Diagnosed Prevalent Cases of DEE (in 2021)\"},\"subtitle\":{\"text\":\"Developmental and Epileptic Encephalopathy Epidemiology Forecast - 2032\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Geography\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Geography \\\"\\n\\\"7MM\\\";253\\n\\\"US\\\";129\\n\\\"Germany \\\";21\\n\\\"France\\\";17\\n\\\"Japan\\\";23\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"credits\":{\"text\":\"Development and Epileptic Encephalopathy Epidemiology Forecast - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-epidemiology-forecast\"},\"legend\":{\"enabled\":false},\"yAxis\":[{\"title\":{\"text\":\"Diagnosed Prevalent Cases in Thousands \"}}]};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-0ef0acc1-56d3-494c-a915-5608ef2f906e\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>DelveInsight estimates that in the EU5 countries, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-epidemiology-forecast\">diagnosed prevalent population of Developmental and Epileptic Encephalopathy<\/a> was maximum in <strong>Germany <\/strong>with <strong>21,041 cases<\/strong>, followed by <strong>France <\/strong>with <strong>17,258 cases<\/strong> in 2021. While the least number of cases were in <strong>Spain<\/strong>, with <strong>11,743 cases<\/strong> in 2021. Whereas, <strong>Japan <\/strong>accounted for <strong>23,798 <\/strong>diagnosed prevalent DEE cases in 2021.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Developmental_and_Epileptic_Encephalopathy_Market_Insights\"><\/span><strong>Developmental and Epileptic Encephalopathy Market Insights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The dynamics of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\">Developmental and Epileptic Encephalopathy (DEE) market<\/a> are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period. Key players such as <strong>Epygenix, Xenon Pharmaceuticals, Longboard Pharmaceuticals, Stoke Therapeutics, Takeda\/Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Praxis Precision Medicines,<\/strong> <strong>Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, BioPharm Solutions,<\/strong> and others are involved in developing&nbsp; Developmental and Epileptic Encephalopathy treatment.<\/p>\n\n\n\n<p>As per an analysis by DelveInsight, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\">Developmental and Epileptic Encephalopathy market<\/a> size is estimated to be&nbsp; <strong>USD 1,371 million<\/strong> in 2021, which is expected to show a positive growth at a <strong>CAGR of 15.5%<\/strong> during the study period 2019\u20132032. The United States accounts for the largest Developmental and Epileptic Encephalopathy market size in comparison to EU5 and Japan, which was estimated to be <strong>USD 1,030 million<\/strong> in 2021.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-57fafa4e-4aaf-4d2c-911f-8aa43efc302b\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-4ytiiji-438-\"><rect fill=\"none\" height=\"426\" width=\"292\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-4ytiiji-444-\"><rect fill=\"none\" height=\"426\" width=\"292\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-4ytiiji-445-\"><rect fill=\"none\" height=\"292\" width=\"426\" x=\"73\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"292\" width=\"426\" x=\"73\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 73 129.5 L 499 129.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 73 188.5 L 499 188.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 73 246.5 L 499 246.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 73 305.5 L 499 305.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 73 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 73 71.5 L 499 71.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 72.5 71 L 72.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 143.5 71 L 143.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 214.5 71 L 214.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 285.5 71 L 285.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 356.5 71 L 356.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 427.5 71 L 427.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 499.5 71 L 499.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"292\" width=\"426\" x=\"73\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 72.5 71 L 72.5 363\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 73 363 L 499 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-4ytiiji-444-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(499,363) rotate(90) scale(-1,1) scale(1 1)\"><rect aria-label=\"7MM, 1,371. Numbers in Million (USD).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"389\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"29\" x=\"248.5\" y=\"37.5\"><\/rect><rect aria-label=\"US, 1,030. Numbers in Million (USD).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"293\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"29\" x=\"189.5\" y=\"133.5\"><\/rect><rect aria-label=\"Germany, 72. Numbers in Million (USD).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"20\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"29\" x=\"131.5\" y=\"406.5\"><\/rect><rect aria-label=\"Spain, 45. Numbers in Million (USD).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"13\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"29\" x=\"73.5\" y=\"413.5\"><\/rect><rect aria-label=\"Japan, 53. Numbers in Million (USD).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"15\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"29\" x=\"14.5\" y=\"411.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(499,363) rotate(90) scale(-1,1) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">DEE Market Size (in 2021)<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"52\">Developmental and Epileptic Encephalopathy Market Insights - 2032<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(73,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(389,17)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">1 371<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>1 371<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(293,76)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">1 030<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>1 030<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(20,134)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">72<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>72<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(13,192)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">45<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>45<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(15,251)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">53<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>53<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"58\" y=\"104\">7MM<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"58\" y=\"163\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"58\" y=\"221\">Germany<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"58\" y=\"279\">Spain<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"58\" y=\"338\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"73\" y=\"382\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"357\" y=\"382\">1000<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"144\" y=\"382\">250<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"215\" y=\"382\">500<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"286\" y=\"382\">750<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"428\" y=\"382\">1250<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"484.9666500091553\" y=\"382\">1500<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Developmental and Epileptic Encephalopathy Market Insights - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Developmental and Epileptic Encephalopathy Market Insights - 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-4ytiiji-445-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"DEE Market Size (in 2021)\"},\"subtitle\":{\"text\":\"Developmental and Epileptic Encephalopathy Market Insights - 2032\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"inverted\":true,\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Numbers in Million (USD)\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Numbers in Million (USD)\\\"\\n\\\"7MM\\\";1371\\n\\\"US\\\";1030\\n\\\"Germany\\\";72\\n\\\"Spain\\\";45\\n\\\"Japan\\\";53\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"\"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Developmental and Epileptic Encephalopathy Market Insights - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-57fafa4e-4aaf-4d2c-911f-8aa43efc302b\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>Among the EU5 countries, <strong>Germany <\/strong>had the highest Developmental and Epileptic Encephalopathy market size with <strong>USD 72 million <\/strong>in 2021, while <strong>Spain <\/strong>had the lowest market size with <strong>USD 45 million<\/strong> in 2021. The Developmental and Epileptic Encephalopathy (DEE) market for Japan accounted for <strong>USD 53 million in 2021.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Developmental_and_Epileptic_Encephalopathy_Treatment_Landscape\"><\/span><strong>Current Developmental and Epileptic Encephalopathy Treatment Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The approach to the Epileptic Encephalopathy treatment guidelines are similar to pediatric epilepsy treatment. The most appropriate anti-epileptic treatment is selected based on the type of <a href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-pipeline-insight\">epilepsy syndrome<\/a>. <strong>Anti-seizure medications<\/strong> are routinely used, but some types of seizures are usually difficult to control. It is the primary way in which epileptic seizures are controlled and is almost always the first class of therapy medications.<strong> Steroid therapy<\/strong> with <strong>Adrenocorticotropic hormone (ACTH) <\/strong>or <strong>prednisone <\/strong>has been helpful in some children. In the patients, a <strong>vagus nerve stimulator<\/strong> or the<strong> ketogenic diet<\/strong> may also be considered when medicines do not work well.<\/p>\n\n\n\n<p><strong>Epidiolex (Cannabidol)<\/strong> developed by <strong>Jazz Pharmaceuticals,<\/strong> formerly <strong>GWP42003-P, <\/strong>also known as <strong>Epidyolex<\/strong> in Europe, is the first prescription, plant-derived cannabis oral formulation developed by <strong>GW pharmaceuticals<\/strong>. It is a novel class of antiepileptic medications with a different mechanism of action. It has been approved in the US and Europe for seizure treatment associated with LGS or Dravet syndrome in patients 2 years of age and older. <a href=\"https:\/\/www.delveinsight.com\/report-store\/epidiolex-cannabidiol-drug-insight-market-forecast\">Epidiolex<\/a> is the <strong>first FDA-approved drug<\/strong> that contains a purified drug substance derived from marijuana, and the active ingredient is cannabidiol (CBD).<\/p>\n\n\n\n<p><strong>Diacomit (<\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/dravet-syndrome-market\"><strong>Stiripentol<\/strong><\/a><strong>)<\/strong> by <strong>Biocodex <\/strong>is another FDA-approved drug for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam. It is an original anti-epileptic drug resulting from<strong> Biocodex\u2019s research program<\/strong>, which was approved in August 2018.<\/p>\n\n\n\n<p>In <strong>March 2022, UCB<\/strong> announced the US FDA approved <a href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sanofi-novartis-argenx-viiv-cullinan-ucb\"><strong>Fintepla<\/strong><\/a><strong> (Fenfluramine)<\/strong>, an oral solution for seizure treatment associated with LGS in patients 2 years of age and older. Fintepla&nbsp; developed by <strong>Zogenix<\/strong> and now acquired by UCB is a low-dose solution of fenfluramine hydrochloride. It prevents the entry of calcium ions into nerve cells, lowering their over-excitability and reducing seizure episodes. It also activates serotonin receptors, which contributes to the overall antiepileptic action.&nbsp;<\/p>\n\n\n\n<p>Recently, on <strong>March 18, 2022, <\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bms-biogen-marinus-merck-takeda-vitaris\"><strong>Ztalmy (ganaxolone)<\/strong><\/a> developed by <strong>Marinus Pharmaceuticals,<\/strong> was FDA approved to treat seizures associated with <strong>cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) <\/strong>in patients 2 years of age and older. This is the first treatment for seizures associated with CDD and the first treatment specifically for CDD.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><em>Browse through our Infographics section to know more about <\/em><a href=\"https:\/\/www.delveinsight.com\/infographics\/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market\"><strong><em>cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder<\/em><\/strong><\/a><\/p><\/blockquote>\n\n\n\n<p><strong>Steroid therapy<\/strong> with <strong>Adrenocorticotropic hormone (ACTH)<\/strong> or <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/prednisone\"><strong>prednisone<\/strong><\/a> has been helpful in some children. Steroids are often an effective treatment for West\u2019s syndrome. Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. The <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/corticosteroids\">short-term effects of corticosteroids<\/a> are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. ACTH promotes the release of glucocorticoids, and most ACTH effects on the central nervous system have been attributed to the activation of glucocorticoid receptors.<\/p>\n\n\n\n<p><strong>Epilepsy surgery<\/strong> may be an option in children with seizures starting in one area or involving one side of the brain. In these situations, a focal resection (removal of one area) or a hemispherectomy (removing most of one side of the brain) may be considered.<\/p>\n\n\n\n<p>The current&nbsp; Developmental and Epileptic Encephalopathy treatment is mainly dominated by the use of Anti-epileptic drugs (AEDs) which are the early treatment choice for almost all patients with multiple seizures. Expected Launch of potential therapies <strong>Epygenix (EPX-100), (EPX-200) (Lorcaserin) and (EPX-300), Neurocrine Biosciences (NBI-921352) (XEN901Xenon Pharmaceuticals (XEN 496), Takeda (Soticlestat) (OV935\/TAK-935), Praxis Precision Medicines (PRAX-562), <\/strong>and others may increase&nbsp; Developmental and Epileptic Encephalopathy market size in the coming years, assisted by an increase in Developmental and Epileptic Encephalopathy population.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165747\/Pioneers-in-the-field-of-Developmental-and-Epileptic-Encephalopathy.png\" alt=\"Pioneers in the field of Developmental and Epileptic Encephalopathy\" class=\"wp-image-17449\" width=\"951\" height=\"486\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165747\/Pioneers-in-the-field-of-Developmental-and-Epileptic-Encephalopathy.png 951w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165747\/Pioneers-in-the-field-of-Developmental-and-Epileptic-Encephalopathy-300x153.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165747\/Pioneers-in-the-field-of-Developmental-and-Epileptic-Encephalopathy-150x77.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165747\/Pioneers-in-the-field-of-Developmental-and-Epileptic-Encephalopathy-768x392.png 768w\" sizes=\"(max-width: 951px) 100vw, 951px\" \/><figcaption><strong>Major Developmental and Epileptic Encephalopathy Market Players<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emerging_Drugs_in_Developmental_and_Epileptic_Encephalopathy_Pipeline\"><\/span><strong>Emerging Drugs in Developmental and Epileptic Encephalopathy Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current therapeutic landscape of Developmental and Epileptic Encephalopathy (DEE) is driven by treatment practices and the expected launch of emerging therapies. Besides, these Developmental and Epileptic Encephalopathy therapies are expected to combat the current unmet needs faced by the patients and add to the overall growth of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\">Developmental and Epileptic Encephalopathy market size<\/a>. Many key Developmental and Epileptic Encephalopathy players such as Epygenix, Longboard Pharmaceuticals, Xenon Pharmaceuticals, Stoke Therapeutics, and others are involved in developing Developmental and Epileptic Encephalopathy treatment therapies which include some of the following -<\/p>\n\n\n\n<p><strong>Epygenix\u2019s<\/strong> lead product candidate, <strong>EPX-100, <\/strong>is a repurposed antihistamine which was used in the past to treat itchiness. The medication can suppress seizures via modulation of serotonin (5HT) signaling pathways, which is different from its anti-histaminic properties. Currently, the drug is in <strong>Phase II trial <\/strong>as a single pivotal study to compare the efficacy of EPX-100 against placebo as adjunctive therapy in 60 patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-pipeline-insight\">Dravet Syndrome<\/a>. Apart from this, EPX-100 is also evaluated as a single pivotal study in the Phase II trial as Adjunctive Therapy in Children with LGS. Moreover, the company is also investigating <strong>EPX-200<\/strong> and<strong> EPX-300<\/strong> for Dravet syndrome and LGS. Furthermore, these drugs can progress directly into Phase III trials and pursue approval. In addition to that, Epygenix expects to start the <strong>Phase III trial<\/strong> for EPX-200 and EPX-300 in the first half of 2022.<\/p>\n\n\n\n<p><strong>XEN496<\/strong> is a pediatric formulation of ezogabine (retigabine), a neuronal KCNQ (Kv7) potassium channel modulator under development by <strong>Xenon Pharmaceuticals<\/strong> as a precision medicine treatment for <strong>KCNQ2-related neonatal developmental and epileptic encephalopathy (KCNQ2-DEE)<\/strong>. Moreover, a Phase III randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial, called the <strong>\u201cEPIK\u201d study<\/strong>, is underway to evaluate the efficacy, safety, and tolerability of XEN496 administered as adjunctive treatment in approximately 40 pediatric patients aged 1 month to less than 6 years with KCNQ2-DEE. Xenon anticipates that the EPIK study (NCT04639310) will be completed in the first half of 2023.<\/p>\n\n\n\n<p><strong>LP352<\/strong> by <strong>Longboard Pharmaceuticals<\/strong> is an oral, centrally acting, 5-HT2c superagonist in development for the potential treatment of seizures associated with DEEs such as Dravet syndrome, LGS, <a href=\"https:\/\/www.delveinsight.com\/report-store\/tuberous-sclerosis-complex-market\">tuberous sclerosis complex<\/a> (TSC), <a href=\"https:\/\/www.delveinsight.com\/report-store\/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market\">CDKL5 deficiency disorder<\/a> (CDD), and other epileptic disorders. LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures. LP352 is the only 5-HT2c receptor superagonist being dose-optimized for the refractory epilepsy population.<\/p>\n\n\n\n<p><strong>STK-001<\/strong> is developed by<strong> Stoke Therapeutics<\/strong>, which is an investigational new medicine for Dravet syndrome treatment. It is a proprietary antisense oligonucleotide (ASO) and has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. The drug is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrences of seizures and significant non-seizure comorbidities. This RNA-based approach is not gene therapy but rather RNA modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (DNA).<\/p>\n\n\n\n<p><strong>Soticlestat (OV935\/TAK-935)<\/strong> by <strong>Takeda\/Ovid Therapeutics<\/strong> is a potent, highly-selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce <a href=\"https:\/\/www.delveinsight.com\/report-store\/seizures-pipeline-insight\">seizure susceptibility<\/a> and improve seizure control. CH24H is predominantly expressed in the brain, where it plays a central role in cholesterol homeostasis.<\/p>\n\n\n\n<p>In addition to these, there are many other companies that are investigating their lead candidate for Developmental and Epileptic Encephalopathy treatment including<strong> PRAX-562 (Praxis Precision Medicines), JBPOS0101 (BioPharm Solutions), XEN901 (Neurocrine Biosciences)<\/strong>, and others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Unmet_Needs_in_Developmental_and_Epileptic_Encephalopathy_Treatment_Domain\"><\/span><strong>Unmet Needs in Developmental and Epileptic Encephalopathy Treatment Domain<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The rare epileptic syndromes, such as LGS, Dravet Syndrome, and CDKL5 deficiency disorder, are extremely complex and heterogeneous diseases with multiple etiologies, resulting in several epilepsy diagnosis challenges as the disease evolves through time. Also, there is a lack of agreed recommendations on the screening and treatment of comorbidities in rare epilepsies. Anti-seizure drugs are currently the standard of care, although they merely treat Developmental and Epileptic Encephalopathy symptoms and do not address the disease\u2019s underlying cause. In addition, there are no approved therapies for the majority of Developmental and Epileptic Encephalopathy types, and off-label choices are associated with poor results, safety, and tolerability. In addition to that,&nbsp; the approved drugs like Fintepla and Ztalmy might deal with high cost of treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Way_Ahead\"><\/span><strong>Way Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Ztalmy, the first licensed therapy for CDKL5 Deficiency Disorder, was recently FDA approved in the United States boosting the growth of the Developmental and Epileptic Encephalopathy market. The current competitive scenario of Developmental and Epileptic Encephalopathy is only restricted to a few therapies. A lack of many approved therapies have created a vacuum of licensed medications that will be filled by further R&amp;D advancement. Emerging drugs with improved seizure control may positively impact the DEE treatment landscape and patients\u2019 quality of life. With robust uptake, Epidiolex and Fintepla continue to add new prescribers and increase their existing prescriber base. Currently, the Developmental and Epileptic Encephalopathy market seems to be an unexplored area by pharmaceutical companies, and thus the companies have a significant opportunity to grab the potential Developmental and Epileptic Encephalopathy market space.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165858\/Developmental-and-Epileptic-Encephalopathy-Market-1024x256.png\" alt=\"Developmental and Epileptic Encephalopathy Market\" class=\"wp-image-17450\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165858\/Developmental-and-Epileptic-Encephalopathy-Market-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165858\/Developmental-and-Epileptic-Encephalopathy-Market-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165858\/Developmental-and-Epileptic-Encephalopathy-Market-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165858\/Developmental-and-Epileptic-Encephalopathy-Market-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165858\/Developmental-and-Epileptic-Encephalopathy-Market-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165858\/Developmental-and-Epileptic-Encephalopathy-Market-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23165858\/Developmental-and-Epileptic-Encephalopathy-Market.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1653303494131\"><strong class=\"schema-faq-question\"><strong>What is Developmental Epileptic Encephalopathy?<\/strong><\/strong> <p class=\"schema-faq-answer\">Developmental and epileptic encephalopathy is considered to be a seizure disorder characterized by a type of seizure known as infantile spasms. The spasms usually appear before the age of 1.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1653303530596\"><strong class=\"schema-faq-question\"><strong>What causes Epileptic Encephalopathy?<\/strong><\/strong> <p class=\"schema-faq-answer\">The most common Epileptic Encephalopathy cause in infancy are structural abnormalities, either congenital (such as malformations of cortical development) or acquired (such as hypoxic-ischemic insults).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1653303545478\"><strong class=\"schema-faq-question\"><strong>Is Developmental and Epileptic Encephalopathy fatal?<\/strong><\/strong> <p class=\"schema-faq-answer\">Developmental and Epileptic Encephalopathy prognosis is very poor. Usually described as a progressive and untreatable disease, this rare disease is also associated with severe physical and cognitive disabilities and unexplained death.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1653303569265\"><strong class=\"schema-faq-question\"><strong>How is Epileptic Encephalopathy diagnosis done?<\/strong><\/strong> <p class=\"schema-faq-answer\">The EEG often evolves to atypical hypsarrhythmia which is transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. In Developmental and Epileptic Encephalopathy, cognitive functions are influenced severely by seizures and [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":17452,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22276,22275,22277,19366],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-17441","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-dee-market","tag-dee-therapies","tag-dee-treatment","tag-vagus-nerve-stimulation","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Developmental and Epileptic Encephalopathy Treatment Landscape<\/title>\n<meta name=\"description\" content=\"Developmental and Epileptic Encephalopathy Therapeutics market seems unexplored, and thus companies are developing therapies to grab market\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Developmental and Epileptic Encephalopathy Treatment Landscape\" \/>\n<meta property=\"og:description\" content=\"Developmental and Epileptic Encephalopathy Therapeutics market seems unexplored, and thus companies are developing therapies to grab market\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-23T14:40:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T07:55:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23175302\/featured-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Developmental and Epileptic Encephalopathy Treatment Landscape","description":"Developmental and Epileptic Encephalopathy Therapeutics market seems unexplored, and thus companies are developing therapies to grab market","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies","og_locale":"en_US","og_type":"article","og_title":"Developmental and Epileptic Encephalopathy Treatment Landscape","og_description":"Developmental and Epileptic Encephalopathy Therapeutics market seems unexplored, and thus companies are developing therapies to grab market","og_url":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-05-23T14:40:57+00:00","article_modified_time":"2024-09-18T07:55:32+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23175302\/featured-image.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies","url":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies","name":"Developmental and Epileptic Encephalopathy Treatment Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23175302\/featured-image.jpg","datePublished":"2022-05-23T14:40:57+00:00","dateModified":"2024-09-18T07:55:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Developmental and Epileptic Encephalopathy Therapeutics market seems unexplored, and thus companies are developing therapies to grab market","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303494131"},{"@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303530596"},{"@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303545478"},{"@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303569265"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23175302\/featured-image.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23175302\/featured-image.jpg","width":772,"height":482,"caption":"Developmental and Epileptic Encephalopathy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303494131","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303494131","name":"What is Developmental Epileptic Encephalopathy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Developmental and epileptic encephalopathy is considered to be a seizure disorder characterized by a type of seizure known as infantile spasms. The spasms usually appear before the age of 1.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303530596","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303530596","name":"What causes Epileptic Encephalopathy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The most common Epileptic Encephalopathy cause in infancy are structural abnormalities, either congenital (such as malformations of cortical development) or acquired (such as hypoxic-ischemic insults).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303545478","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303545478","name":"Is Developmental and Epileptic Encephalopathy fatal?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Developmental and Epileptic Encephalopathy prognosis is very poor. Usually described as a progressive and untreatable disease, this rare disease is also associated with severe physical and cognitive disabilities and unexplained death.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303569265","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/developmental-and-epileptic-encephalopathy-pipeline-therapies#faq-question-1653303569265","name":"How is Epileptic Encephalopathy diagnosis done?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The EEG often evolves to atypical hypsarrhythmia which is transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/23175302\/featured-image-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">vagus nerve stimulation<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DEE Market<\/span>","<span class=\"advgb-post-tax-term\">DEE Therapies<\/span>","<span class=\"advgb-post-tax-term\">DEE Treatment<\/span>","<span class=\"advgb-post-tax-term\">vagus nerve stimulation<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 23, 2022","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on May 23, 2022 8:10 pm","modified":"Updated on Sep 18, 2024 1:25 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17441"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17441\/revisions"}],"predecessor-version":[{"id":29600,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17441\/revisions\/29600"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17452"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17441"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17441"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}